IPX203 clinical trials
Also written IPX203.
How each study uses IPX203 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IPX203 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test IPX203.
- Feb 2027BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's DiseasePhase 4 · The Cleveland Clinic
Studies
Open first, then newest update. How each study uses IPX203 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's DiseaseRecruitingPhase 4The Cleveland ClinicNCT07138560Written as CREXONT ER
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseaseRecruitingPhase 4Impax Laboratories, LLCNCT06765668Written as CREXONT ER
- Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor FluctuationsCompletedPhase 3Impax Laboratories, LLCNCT03877510Written as IPX203
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsCompletedPhase 3Impax Laboratories, LLCNCT03670953Written as IPX203 ER CD-LD
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseCompletedPhase 2Impax Laboratories, LLCNCT03007888Written as IPX203
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseaseCompletedPhase 2Impax Laboratories, LLCNCT02271503Written as IPX203 180 mg